Two men share securities regulation news

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Securities Regulation Daily, September 30, 2016

GlaxoSmithKline to pay $20M to settle Chinese bribery charges

By Amy Leisinger, J.D.

The SEC has charged GlaxoSmithKline with violations of the internal controls and recordkeeping provisions of the Foreign Corrupt Practices Act. According to the Commission, the company engaged in a scheme to provide gifts to certain Chinese individuals and entities in order to improperly influence them and falsely recorded the transactions as legitimate expenses in its books and records. Without admitting or denying the allegations, the company agreed to review and report to the SEC on its remediation of its compliance measures and to pay a $20-million civil penalty (In the Matter of GlaxoSmithKline plcRelease No. 34-79005, September 30, 2016).

Bribery scheme. GlaxoSmithKline plc (GSK) is a global provider of pharmaceutical and health care products organized in the U.K. with a subsidiary and a joint venture operating in China. The SEC alleged that, from at 2010 to June 2013, employees and agents of the GSK’s Chinese operations engaged in transactions to corruptly transfer things of value to foreign officials and healthcare professionals to increase sales of GSK’s pharmaceutical products.

According to the Commission, the corrupt payments included gifts, coverage of improper travel and entertainment expenses, and cash. These improper practices were pervasive among representatives of the Chinese entities and condoned by management, the SEC contended, and were facilitated in part by the use of third parties that purported provided legitimate services. The costs associated with these payments were recorded in GSK’s books and records as legitimate expenses, such as associational sponsorships, employee expenses, conference fees, and marketing costs.

Throughout the period, GSK failed to devise and maintain a sufficient system of internal accounting controls and lacked an effective anti-corruption compliance program, the SEC stated, and these deficiencies also led to similar improper activities in other countries. By its conduct, the Commission alleged, GSK violated Exchange Act Sections 13(b)(2)(A) and (B).

Sanctions. In determining to accept GSK’s settlement offer, the Commission considered the company’s remedial acts, including its disclosure of findings from an internal investigation and its efforts to enhance its compliance programs and global risk assessment processes. GSK agreed to report to the Commission staff periodically on the status of its implementation of compliance measures and to provide a complete description of its Foreign Corrupt Practices Act and anti-corruption related remediation efforts. The company also agreed to cease and desist from further violations in addition to payment of the civil penalty.

The release is No. 34-79005.

Companies: GlaxoSmithKline plc

MainStory: TopStory Enforcement FraudManipulation InternationalNews

Back to Top

Securities Regulation Daily

Introducing Wolters Kluwer Securities Regulation Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.

A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.